VYNE Therapeutics Inc.

NASDAQ (USD): VYNE Therapeutics Inc. (VYNE)

Last Price

1.89

Today's Change

-0.03 (1.56%)

Day's Change

1.83 - 1.91

Trading Volume

24,357

Overview

Market Cap

27 Million

Shares Outstanding

14 Million

Avg Volume

63,708

Avg Price (50 Days)

2.41

Avg Price (200 Days)

2.66

PE Ratio

-1.67

EPS

-1.13

Earnings Announcement

12-Aug-2024

Previous Close

1.92

Open

1.86

Day's Range

1.8374 - 1.91

Year Range

1.57 - 6.789

Trading Volume

24,368

Price Change Highlight

1 Day Change

-1.56%

5 Day Change

16.67%

1 Month Change

-25.59%

3 Month Change

-37.42%

6 Month Change

-17.11%

Ytd Change

-17.11%

1 Year Change

-53.33%

3 Year Change

-96.79%

5 Year Change

-99.55%

10 Year Change

-99.91%

Max Change

-99.91%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment